- Tension: GLP-1 weight-loss drugs were designed to reduce appetite, but users are reporting something unexpected: a sudden resurgence of hobbies, friendships, and joy they hadn’t felt in years.
- Noise: We assume behavioral change must be earned through willpower and suffering — and we’re deeply uncomfortable with the idea that a medication could unlock creativity, connection, and pleasure alongside weight loss.
- Direct Message: For many people, the gap between who they are and who they want to be was never a moral failing — it was neurochemical. When the noise of compulsive craving finally quieted, they didn’t need to be told how to live. They already knew.
To learn more about our editorial approach, explore The Direct Message methodology.
Last October, Denise Alvarez, a 51-year-old dental office manager in San Antonio, started semaglutide after years of struggling with her weight. By December, she’d lost 18 pounds. But that’s not the part that surprised her. The part that surprised her was the watercolors.
\p>”I was at Target buying toothpaste,” she told me, “and I walked past the art supplies aisle and just — stopped. I hadn’t painted since high school. I bought a set of watercolors and a pad of paper, and that night I sat at the kitchen table for two hours just messing around.” She paused. “I can’t explain it. I didn’t decide to become a painter. Something just… opened up.”
Denise isn’t alone, and this isn’t a quirky anecdote. Across forums, clinical observations, and a growing body of early research, people on GLP-1 receptor agonists — drugs like Ozempic, Wegovy, and Mounjaro — are reporting something that goes well beyond reduced appetite. They’re picking up instruments they haven’t touched in decades. They’re calling friends they’d lost touch with. They’re going for walks not because a doctor told them to, but because walking suddenly feels good.
The drugs were designed to do one thing. They appear to be doing something else entirely.
The standard explanation for GLP-1 drugs is straightforward: they mimic a hormone that signals fullness, slow gastric emptying, reduce appetite. You eat less. You lose weight. End of story. But the brain is never an end-of-story organ, and GLP-1 receptors don’t just live in the gut. They’re densely clustered in the brain’s reward circuitry — the nucleus accumbens, the ventral tegmental area, regions that govern craving, motivation, pleasure, and the basic architecture of wanting.
This is where things get interesting and, frankly, where the science is still catching up to what patients are experiencing.
A 2023 study published in Nature Medicine found that semaglutide significantly reduced alcohol consumption in people who weren’t even being treated for alcohol use disorder. Other researchers have documented decreases in compulsive shopping, nail-biting, and doom-scrolling. The pattern isn’t just “less hunger.” It’s something closer to a quieting of the noise — the constant background hum of craving that many people didn’t even realize was there until it stopped.
Marcus Tillman, a 44-year-old IT project manager in Raleigh, put it this way: “I used to come home from work and it was like this pull — food, phone, couch, food, phone, couch. Every night. I wasn’t even enjoying it. I was just… cycling.” Three months on tirzepatide, Marcus noticed the pull had weakened. “One evening I just didn’t sit down. I went to the garage and started organizing my tools. Then I started building a shelf. Then I signed up for a woodworking class at the community college.” He laughed. “My wife thought I was having an affair because I was suddenly so energized.”
What Marcus describes isn’t willpower. It’s not a motivational breakthrough. It’s what happens when the reward system recalibrates — when the brain’s default loop of seeking easy dopamine hits gets quieter, and there’s suddenly room for something else. Researchers call this “cognitive bandwidth” — the mental resources freed up when you’re no longer fighting a constant internal negotiation with craving. And it maps onto something we’ve explored before about habits that fog our brains: when the cycle of compulsion loosens, clarity doesn’t just return. It expands.
But here’s where the cultural narrative gets tangled. Because we live in a world that is deeply uncomfortable with the idea that a medication could unlock joy. Weight loss? Fine — we understand that transactionally. Take a drug, lose pounds. But happiness? Reconnection? Creativity? That’s supposed to come from discipline, from therapy, from spiritual awakening. Not from an injection pen you keep in the fridge.
The discomfort is revealing. It exposes something about how we think about willpower — specifically, the almost religious belief that behavioral change must be earned through suffering. As a piece on late-life regrets highlighted, so many people spend decades knowing exactly what would make them feel alive — hobbies, friendships, movement, rest — but can’t seem to access it. The barrier was never knowledge. It was something more biological, more stubborn, more woven into the wiring.
Raquel Ferreira, a 38-year-old nurse in Portland, Oregon, has been on Wegovy for seven months. She’s lost 30 pounds, yes, but she wants to talk about the phone calls. “I have this group of friends from nursing school. We were so close. Over the years I just — stopped reaching out. Not because I didn’t love them. I was just always so tired, and calling someone felt like another task on the list.” She started calling again in month three. Now they have a standing Thursday night video chat. “It doesn’t feel like effort anymore. It feels like something I want.”
That distinction — between effort and desire — is the fulcrum. Research from the University of Pennsylvania has begun exploring how GLP-1 drugs affect not just appetite but anhedonia — the clinical term for the inability to feel pleasure. Anhedonia isn’t depression, exactly. It’s the flattening of want. The grayness that makes everything feel like it requires more energy than it’s worth. And it appears that for some people, these drugs are lifting that particular veil.
This doesn’t mean the drugs are a happiness pill. They’re not. The side effects are real — nausea, fatigue, muscle loss, the still-unknown long-term risks. And there are legitimate concerns about what happens when people stop taking them, whether the old patterns come roaring back. As we’ve discussed in the context of self-care rituals that genuinely improve mental wellbeing, sustainable change usually needs more than one pillar. A drug can open a door. But you still have to walk through it and build something on the other side.
What’s worth sitting with, though, is the sheer number of people who are describing the same thing in remarkably similar language. “Something opened up.” “The noise stopped.” “I had room to think about what I actually wanted.” These aren’t the words of people who are simply eating less. These are the words of people experiencing a shift in the relationship between their brain and their life — a loosening of the grip that compulsive reward-seeking had on every waking hour.
And maybe that’s the part worth paying attention to. Not the weight loss. Not the before-and-after photos that dominate celebrity coverage and social media debates. But the quieter transformation underneath — the one that looks like a woman buying watercolors on a Tuesday night, or a man building a shelf in his garage, or a nurse calling friends she thought she’d outgrown.
For decades, we told people that if they just tried harder, they’d eat better, move more, reconnect, create, live fully. And when they couldn’t, we blamed character. We blamed laziness. We built entire industries — diet culture, productivity culture, wellness culture — around the idea that the gap between who you are and who you want to be is a moral failing you can purchase your way out of.
What these drugs are quietly suggesting is something more unsettling and more compassionate: that for many people, the gap was never moral. It was neurochemical. The person they wanted to be was right there the whole time — buried under a reward system that had been hijacked by modern food, modern stress, modern everything. And when the noise finally went quiet, they didn’t need to be told what to do.
They already knew. They’d always known.
Denise still paints most evenings. She’s not great at it — her words, not mine. But that’s not the point, and she knows it. “For the first time in maybe twenty years,” she said, “I’m doing something just because it makes me feel like myself.”
That sentence deserves to be read slowly. Not because it’s about a drug. But because it’s about all the years before the drug — and the quiet tragedy of a self that was always there, waiting to be heard over the noise.
Feature image by Kampus Production on Pexels
